FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INVOKAMET XR, a fixed-dose combination of canagliflozin and metformin hydrochloride, by Janssen Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)

Snippet

SUPPL AP for INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)